ArticleOncoimmunology2016

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.

Shaodong Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.